Date: 2011-12-07
Type of information: Subvention
Company: EMBL Ventures (Germany)
Investors:
Amount: €40 million
Funding type:
Planned used:
Others: EMBL Ventures,a dedicated early stage life science investor and the venture capital arm of the European Molecular Biology Laboratory (EMBL), has announced the €40 million first close of the EMBL Technology Fund II (ETF II). Building on the scientific excellence of EMBL, EMBL Ventures remains focused on Life Sciences investments primarily in European biotechnology and medtech companies with innovative early stage technologies and products that have the potential to become first in class. EMBL Ventures plans to commit between €2 million and €5 million per investment. Companies that EMBL Ventures has pro-actively founded or invested in include Affectis Pharmaceuticals (Multiple Sclerosis, Pain), Elara Pharmaceuticals (Oncology), Endoart (Adipositas), Fibrex Medical (Cardiology), Immatics Biotechnologies (Oncology) and Lipid Therapeutics (Gastroenterology).
Therapeutic area:
